Abstract: COVID- 19 an evolved virus emerged as a threat to human life since December 2019, declared a pandemic on 20th January 2020; researchers worldwide are studying several drugs for enabling cure. Prophylaxis using vaccine is not available at present for prevention of COVID- 19. The treatment relies on use of anti- viral drugs; its failure has left no choice other than passive immunisation. The review article aggregates information on (a) Coronavirus case fatally compared to SERS and MERS. A survey on (b) present treatment using anti- viral drugs therapy and its failure (c) plasma therapy, its contingency in cure of COVID- 19 (d) monoclonal antibody therapy and (e) need for immunoprophylaxis (using convalescent plasma therapy or monoclonal antibody therapy) is done. Findings.....
Keywords: COVID- 19, Anti- viral drug, Immunoprophylaxis, Plasma therapy, Convalesent plasma, monoclonal antibody
[1]. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395:507e13, https://doi.org/ 10.1016/S0140-6736(20)30211-7.
[2]. Dong L., Hu s., Gao J., (2020) Discovering drugs to treat Coronavirus disease 2019 (COVID- 19). Drug discovery and Theraputics, 14 (1): 58- 60, doi: 10.5582/ddt.2020.01012
[3]. Fan Y., Zhao K., Shi Z., Zhou P., (2019) Bat Coronaviruses in China, Viruses. 11(3): 210, doi: 10.3390/v11030210
[4]. Haviernik J, Stefanik M, Fojtikova M, Kali S, Tordo N, Rudolf I, Hubalek Z, Eyer L, Ruzek D. Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses. Viruses. 2018 Apr 10; 10(4):184. doi: 10.3390/v10040184. PMID: 29642580; PMCID: PMC5923478.
[5]. Iwasaki, A., Yang, Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0321-6
[6]. Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen. Effectiveness of convalescent plasma therapy in severe COVID-19 patients, PNAS April 28, 2020 117 (17) 9490-9496; first published April 6, 2020 https://doi.org/10.1073/pnas.2004168117.
